Phase II trial of etoposide and cisplatin for refractory small cell lung cancer: a Cancer and Leukemia Group B Study. 1990

S L Graziano, and K Lee, and K J Propert, and R Tinsley, and D M Hayes, and M Green, and R L Comis
Department of Medicine, SUNY-Health Science Center, Syracuse, NY 13210.

A phase II trial of etoposide and cisplatin for patients with previously treated small cell lung cancer was carried out by CALGB from June 1983 to May 1984. Thirty-five evaluable patients who had failed one prior chemotherapy regimen were treated with etoposide 80 mg/m2 and cisplatin 20 mg/m2 days 1-5 every 3 weeks. Objective responses were seen in 7 patients (20%) with 1 complete response and 6 partial responses. The median duration of response was 5.1 months. Fifteen patients (43%) had stable disease. Overall survival was 49% at 6 months and 14% at 1 year. The median survival was 6 months. Toxicity was mainly hematologic with severe and life-threatening leukopenia and thrombocytopenia seen in 71% and 66% of patients, respectively. Two treatment-related deaths caused by infection were seen. This cooperative group study fails to confirm the high response rates previously reported in institutional pilot studies.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

S L Graziano, and K Lee, and K J Propert, and R Tinsley, and D M Hayes, and M Green, and R L Comis
September 1996, Lung cancer (Amsterdam, Netherlands),
S L Graziano, and K Lee, and K J Propert, and R Tinsley, and D M Hayes, and M Green, and R L Comis
December 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
S L Graziano, and K Lee, and K J Propert, and R Tinsley, and D M Hayes, and M Green, and R L Comis
January 1985, Cancer treatment reports,
S L Graziano, and K Lee, and K J Propert, and R Tinsley, and D M Hayes, and M Green, and R L Comis
October 1992, American journal of clinical oncology,
S L Graziano, and K Lee, and K J Propert, and R Tinsley, and D M Hayes, and M Green, and R L Comis
January 1993, Medical and pediatric oncology,
S L Graziano, and K Lee, and K J Propert, and R Tinsley, and D M Hayes, and M Green, and R L Comis
April 1993, American journal of clinical oncology,
S L Graziano, and K Lee, and K J Propert, and R Tinsley, and D M Hayes, and M Green, and R L Comis
June 1994, American journal of clinical oncology,
S L Graziano, and K Lee, and K J Propert, and R Tinsley, and D M Hayes, and M Green, and R L Comis
October 2011, Cancer chemotherapy and pharmacology,
S L Graziano, and K Lee, and K J Propert, and R Tinsley, and D M Hayes, and M Green, and R L Comis
May 1986, Cancer treatment reports,
S L Graziano, and K Lee, and K J Propert, and R Tinsley, and D M Hayes, and M Green, and R L Comis
November 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Copied contents to your clipboard!